Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual
BRIDGEWATER, NJ / ACCESSWIRE / May 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in
Tharimmune Announces 1-for-15 Reverse Stock Split bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.
Met primary study endpoints: good safety profile and reduction in central subfield thickness First oral therapy to demonstrate reduction in macular edema; supports potential for early disease.
Rezolute Inc. (RZLT) Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.